



**GLESENER  
PHARMACY**

**NEUROLOGY  
REFERRAL FORM**

Phone: (626) 966-3691 • Fax: (626) 331-8691 • Dedicated Texting: (626) 664-0988

Today's Date: \_\_\_\_\_ Needs By Date: \_\_\_\_\_ SHIP TO:  Patient  Office  Other \_\_\_\_\_

PATIENT INFORMATION				PRESCRIBER INFORMATION			
PATIENT NAME				PRESCRIBER NAME			
ADDRESS				NPI#			
CITY, STATE, ZIP				DEA#		LICENSE#	
MAIN PHONE#		ALT.#		ADDRESS			
SOCIAL SECURITY#				CITY, STATE, ZIP			
DATE OF BIRTH		MALE FEMALE		PHONE#		FAX#	
HEIGHT		WEIGHT		LBS		KG	
ALLERGIES				CONTACT PERSON			
OTHER MEDICATIONS							

CLINICAL INFORMATION	
<b>Diagnosis Code:</b> <input type="checkbox"/> G35 Multiple Sclerosis <input type="checkbox"/> Other _____ <b>History:</b> <ul style="list-style-type: none"> <li>Has the patient been previously treated for this condition? <input type="checkbox"/> Yes <input type="checkbox"/> No Medication failed _____</li> <li>Is the patient currently on therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Medication failed _____</li> <li>Will patient stop taking current therapy before starting new therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No</li> <li>How long will the patient wait before starting the new therapy? _____</li> </ul> Are there other medication patient currently taking? _____	

PRESCRIPTION INFORMATION			QUANTITY	REFILLS
<input type="checkbox"/> Avonex®	<input type="checkbox"/> 30mcg Prefilled Syringe <input type="checkbox"/> 30mcg Vials	<input type="checkbox"/> Inject 30mcg intramuscularly once weekly Other dosing: _____	4 week supply	
<input type="checkbox"/> Betaseron®	<input type="checkbox"/> 0.3mg Prefilled Syringe	<input type="checkbox"/> Initial: Week 1&2: 0.0625mg (0.25 ml), Week 3&4: 0.125mg (0.5ml), Week 5&6: 0.1875mg (0.75ml), Week 7: 0.25mg (1ml) SubQ every other day. <input type="checkbox"/> Maintenance: Inject 0.25mg (1ml) subcutaneously every other day	4 week supply	
<input type="checkbox"/> Copaxone®	<input type="checkbox"/> 20mg Prefilled Syringe	<input type="checkbox"/> Inject 20mg subcutaneously once every day	4 week supply	
<input type="checkbox"/> Extavia®	<input type="checkbox"/> 0.3mg Kit	<input type="checkbox"/> Inject 0.25g subcutaneously every other day	4 week supply	
<input type="checkbox"/> Gilenya®	<input type="checkbox"/> 0.5mg Capsule	<input type="checkbox"/> Take 1 capsule by mouth daily	4 week supply	
<input type="checkbox"/> Rebif®	<input type="checkbox"/> Titration Pack <input type="checkbox"/> 22mcg Prefilled Syringe <input type="checkbox"/> 44mcg Prefilled Syringe	<input type="checkbox"/> Initial: Inject – Week 1&2: 8.8mcg (0.2ml), Week 3&4: 22mcg (0.5ml) subcutaneously three times weekly 48hrs apart <input type="checkbox"/> Maintenance: Inject 22mcg (0.5ml) subcutaneously three times weekly 48hr apart <input type="checkbox"/> Maintenance: Inject 44mcg (0.5ml) subcutaneously three times weekly 48hrs apart <input type="checkbox"/> Other dosing: _____	4 week supply	
<input type="checkbox"/> Other				
<input type="checkbox"/> Epipen®		<input type="checkbox"/> Inject 1 pen into thigh area in case of anaphylaxis; may repeat	2 pen pack	
<input type="checkbox"/> Epipen Jr.®				
<input type="checkbox"/> Tysabri	<input type="checkbox"/> 300mg-Vial	<input type="checkbox"/> 300mg IV Q 4 weeks		<input type="checkbox"/> Other

**INSURANCE: PLEASE FAX COPY OF PRESCRIPTION CARD & MEDICAL CARD FRONT & BACK**

**Prescriber Authorization:** I authorize Glesener Pharmacy and its representatives to act as my authorized agent to initiate the insurance prior authorization process for my patient(s), and to sign any necessary prior authorization forms on my behalf. In the event that Glesener Pharmacy is unable to fulfill this prescription, I further authorize this pharmacy to forward this information and any related materials related to coverage of the product to another pharmacy of the patient's choice or in the patient's insurer's provider network.

**Prescriber's Signature** (no stamps) If Brand required check DAW \_\_\_\_\_ Initials \_\_\_\_\_ Date \_\_\_\_\_

**IMPORTANT NOTICE:** This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.